bevacizumab + irinotecan + panitumumab

This is a combination regimen consisting of three drugs—bevacizumab, irinotecan, and panitumumab—used primarily in the treatment of metastatic colorectal cancer (mCRC), particularly as a second-line therapy after failure of oxaliplatin-based chemotherapy. - **Bevacizumab** is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis and reducing tumor blood supply. - **Irinotecan** is a small molecule topoisomerase I inhibitor that interferes with DNA replication in cancer cells, leading to cell death. - **Panitumumab** is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking downstream signaling pathways involved in cell proliferation and survival. The combination leverages complementary mechanisms to inhibit tumor growth by blocking angiogenesis, interfering with DNA replication, and inhibiting EGFR-mediated signaling pathways. This regimen has been studied for efficacy and safety in patients with mCRC who have failed prior therapies[1][2][6]. The use of this combination may be limited by toxicity concerns; some studies suggest increased adverse events when anti-EGFR and anti-VEGF antibodies are combined[7].

Brand names

VectibixCamptosarAvastin

Other names

panitumumab + irinotecan + bevacizumab